Ascendis Pharma A/S (ASND) has a current Price-to-Book (P/B) ratio of -63.89. Compared to its 3-year average P/B ratio of -32.07, the current P/B ratio is approximately 99.21% higher. Relative to its 5-year average P/B ratio of -14.66, the current P/B ratio is about 335.75% higher. Ascendis Pharma A/S (ASND) has a Forward Free Cash Flow (FCF) yield of approximately -1.00%. Compared to its 3-year average FCF yield of -5.91%, the current FCF yield is approximately -83.03% lower. Relative to its 5-year average FCF yield of -6.49%, the current FCF yield is about -84.53% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ASND competitors is 5.71, providing a benchmark for relative valuation. Ascendis Pharma A/S Corp (ASND.O) exhibits a P/S ratio of 9.51, which is 66.63% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ASND increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ASND in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ASND currently overvalued or undervalued?

What is Ascendis Pharma A/S (ASND) fair value?

ASND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Ascendis Pharma A/S (ASND) is between 210.72 to 294.65 according to relative valuation method.

How does ASND's valuation metrics compare to the industry average?

The average P/S ratio for ASND's competitors is 5.71, providing a benchmark for relative valuation. Ascendis Pharma A/S Corp (ASND) exhibits a P/S ratio of 9.51, which is 66.63% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Ascendis Pharma A/S (ASND) as of Mar 03 2026?

As of Mar 03 2026, Ascendis Pharma A/S (ASND) has a P/B ratio of -63.89. This indicates that the market values ASND at -63.89 times its book value.

What is the current FCF Yield for Ascendis Pharma A/S (ASND) as of Mar 03 2026?

As of Mar 03 2026, Ascendis Pharma A/S (ASND) has a FCF Yield of -1.00%. This means that for every dollar of Ascendis Pharma A/S's market capitalization, the company generates -1.00 cents in free cash flow.

What is the current Forward P/E ratio for Ascendis Pharma A/S (ASND) as of Mar 03 2026?

As of Mar 03 2026, Ascendis Pharma A/S (ASND) has a Forward P/E ratio of 94.95. This means the market is willing to pay $94.95 for every dollar of Ascendis Pharma A/S's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Ascendis Pharma A/S (ASND) as of Mar 03 2026?

As of Mar 03 2026, Ascendis Pharma A/S (ASND) has a Forward P/S ratio of 9.51. This means the market is valuing ASND at $9.51 for every dollar of expected revenue over the next 12 months.

ASND Valuation